Halozyme Therapeutics Inc (HALO)

Price $125.63 · +0.88% today · $14.3B market cap.

biotech_pharma

Strongest Overallmedium risk← Back

Simulated history. Equities don't yet have ingested OHLCV, so the price chart and technical indicators below are illustrative (deterministic, labelled) — not real market history.

Price & Performance

$125.63 -3.8% over 1Y

Simulated history — illustrative, not real market data.

Today

+0.88%

1 week

+2.56%

1 month

+13.80%

1 year

+87.82%

Technical Analysis

RSI (14)

52.50

MACD

0.80

MACD signal

0.29

MACD hist

0.51

SMA 20

124.02

SMA 50

124.39

EMA 20

125.05

ATR (14)

2.90

Support

118.54

Resistance

130.83

Bollinger upper

130.15

Bollinger lower

117.89

▹ RSI 53 — neutral
▹ MACD above signal (bullish)
▹ Price above 20/50-day averages

Indicators describe past price action — they do not predict future direction.

Fundamental Analysis

P/E ratio

34.48

Return on equity

181%

EBITDA

n/a

EPS (TTM)

3.35

Net debt

n/a

Net margin

24.86%

Gross margin

82.42%

Current ratio

2.71

Debt / Equity

14.95

Dividend yield

n/a

Operating margin

35.57%

Revenue growth (YoY)

41.15%

Risk Assessment

Ann. volatility

18.3%

Max drawdown

18.5%

Liquidity

Adequate market capitalization

Leverage

Debt/equity 15.0 (elevated)

Valuation

P/E 34×

Earnings

Earnings dates are not tracked in this release.

Concentration

Single-name equity — no diversification within the position.

Estimated annualized volatility 18% with a maximum drawdown of 19% over the available window.

Investment Thesis (generated summary)

Halozyme Therapeutics Inc (HALO) screens constructively on the current data, with an opportunity score of 70/100. The score reflects the available fundamental, technical, valuation and sentiment inputs — it is a research screen, not a forecast or a recommendation to trade.

Bullish case

Strong net margin (25%)
High leverage (D/E 15.0)
Revenue growing 41% y/y
Moderate P/E (34×)
Positive multi-horizon momentum

Potential catalysts

How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New Highs
BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.
MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress

Horizon: ~1–3 months for technical signals; 12+ months for fundamental quality.

Thesis invalidated if: Momentum reverses and price breaks below its 50-day average; Earnings or guidance disappoint relative to consensus; A sector-level drawdown outweighs stock-specific strength.

News Sentiment

Bullish 25%Neutral 75%Bearish 0%